LV10051A - Liofilizeta ifosfamida iegusanas veids - Google Patents

Liofilizeta ifosfamida iegusanas veids

Info

Publication number
LV10051A
LV10051A LV920174A LV920174A LV10051A LV 10051 A LV10051 A LV 10051A LV 920174 A LV920174 A LV 920174A LV 920174 A LV920174 A LV 920174A LV 10051 A LV10051 A LV 10051A
Authority
LV
Latvia
Prior art keywords
ifosfamida
lyophilisate
ifosfamide
weight
hexitol
Prior art date
Application number
LV920174A
Other languages
English (en)
Other versions
LV10051B (en
Inventor
Uwe-Peter Damann
Otto Isaac
Dieter Sauerbier
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV10051A publication Critical patent/LV10051A/lv
Publication of LV10051B publication Critical patent/LV10051B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Amplifiers (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LVP-92-174A 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide LV10051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (2)

Publication Number Publication Date
LV10051A true LV10051A (lv) 1994-05-10
LV10051B LV10051B (en) 1995-06-20

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-174A LV10051B (en) 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide

Country Status (25)

Country Link
EP (1) EP0265812B1 (lv)
JP (1) JPS63159319A (lv)
KR (1) KR900003491B1 (lv)
AT (1) ATE55250T1 (lv)
AU (1) AU598602B2 (lv)
CA (1) CA1314231C (lv)
DD (1) DD262582A5 (lv)
DE (1) DE3764235D1 (lv)
DK (1) DK169308B1 (lv)
EG (1) EG18333A (lv)
ES (1) ES2017982B3 (lv)
FI (1) FI87140C (lv)
GE (1) GEP19971025B (lv)
GR (1) GR3000708T3 (lv)
HU (1) HU197987B (lv)
IL (1) IL84312A (lv)
IN (1) IN168119B (lv)
LV (1) LV10051B (lv)
MX (1) MX8958A (lv)
NO (1) NO873860L (lv)
PT (1) PT86032B (lv)
RU (1) RU1836079C (lv)
UA (1) UA11075A (lv)
YU (1) YU197387A (lv)
ZA (1) ZA878183B (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334083B1 (de) * 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
CA2497898C (en) * 2002-09-05 2012-02-07 Bharat Serums & Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
MXPA05005919A (es) * 2002-12-02 2005-09-21 Bharat Serums & Vaccines Ltd Composiciones de ifosfamida para la administracion parenteral, y un proceso para su preparacion.
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP5619419B2 (ja) * 2006-09-29 2014-11-05 インファ ソシエテ アノニム 薬学的組成物用調剤システム及び静脈内投与用キット
CN105900385B (zh) * 2014-12-04 2019-08-27 华为技术有限公司 在数据通信网中的负载分配

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
RU1836079C (ru) 1993-08-23
DK169308B1 (da) 1994-10-10
EP0265812B1 (de) 1990-08-08
FI87140C (fi) 1992-12-10
IL84312A (en) 1991-11-21
FI87140B (fi) 1992-08-31
MX8958A (es) 1993-12-01
GEP19971025B (en) 1997-04-06
LV10051B (en) 1995-06-20
DD262582A5 (de) 1988-12-07
NO873860L (no) 1988-05-02
IN168119B (lv) 1991-02-09
KR880004814A (ko) 1988-06-27
FI874727A0 (fi) 1987-10-27
UA11075A (uk) 1996-12-25
HUT44932A (en) 1988-05-30
YU197387A (en) 1988-12-31
ZA878183B (en) 1988-05-02
KR900003491B1 (ko) 1990-05-21
DE3764235D1 (de) 1990-09-13
EP0265812A1 (de) 1988-05-04
CA1314231C (en) 1993-03-09
JPH0543684B2 (lv) 1993-07-02
ES2017982B3 (es) 1991-03-16
IL84312A0 (en) 1988-03-31
AU8052987A (en) 1988-05-05
FI874727A (fi) 1988-05-01
NO873860D0 (no) 1987-09-15
HU197987B (en) 1989-07-28
ATE55250T1 (de) 1990-08-15
EG18333A (en) 1993-12-30
DK569687D0 (da) 1987-10-30
GR3000708T3 (en) 1991-10-10
PT86032B (pt) 1990-08-31
PT86032A (de) 1987-11-01
AU598602B2 (en) 1990-06-28
DK569687A (da) 1988-05-01
JPS63159319A (ja) 1988-07-02

Similar Documents

Publication Publication Date Title
FI891283A0 (fi) Ifosfamid-mesna-lyofilisat och foerfarande foer dess framstaellning.
DE3855451T2 (de) Substituiertes 1,4,7-Triscarboxymethyl-1,4,7,10-tetraazacyclododecan und Analoga
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
DK275488A (da) Indolonderivater
ATE66143T1 (de) Feste zubereitung mit langsamer freisetzung.
SE8603582L (sv) Komposition innehallande l-dopa
PH23565A (en) Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient
LV10051A (lv) Liofilizeta ifosfamida iegusanas veids
IT1212143B (it) Composizione ad attivita'tricogena.
DK23490A (da) Implanteret antibiotisk tilberedning med reguleret frigivelse
DK103987A (da) Substituerede 1,3,4,9-tetrahydropyranooe3,4-baaindol-l-eddikesyrer, deres fremstilling og anvendelse som laegemidler
FR2603284B1 (fr) Derives d'acide 7-oxabicyclo(2.2.1.)heptane hydroxamique a action therapeutique
KR900700484A (ko) 1,4:3,6-디안히드로 헥시톨 잘산염의 아미노프로판올 유도체,그의 제법 및 약제로서의 그의 용도
NO167801C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater.
DE3773322D1 (de) Pharmazeutische zubereitungen mit heilender aktivitaet.
IT213056Z2 (it) Accorgimenti per montare celermente gli apripista sui trattori agricoli senza pregiudicare la necessaria resistenza meccanica dell'insieme